Please enable JavaScript or talk to your local administrator to get JavaScript enabled.

Project

Modulation of regulatory T cells in the bladder tumor environment by anti-PD-L1 immunotherapy

Funder: Bladder Cancer Advocacy Network

Funding period
USD 50 K
Funding amount
Abstract
Immunotherapies, specifically checkpoint inhibitors blocking PD ligand-1 (PD-L1) and its inhibitory receptor PD-1, lead to durable responses in a minority of patients with platinum-refractory and platinum-naïve bladder transitional cell carcinoma (TCC), and improved survival in the platinum-refractory setting. However, the features that predict responses, and the immune populations in TCC that are responsible for benefit with anti-PD-1/PD-L1, remain obscure. This proposal addresses the novel hypothesis that anti-PD-L1 modulates the activity of regulatory T cells (Tregs), which we and others have described in TCC, and addresses the following Specific Aims: 1. Does anti-PD-L1 therapy reduce the abundance of Tregs, including in specific spatial microenvironments associated with TCC tumors? 2. Does anti-PD-L1 therapy change the antigenic repertoire of Tregs in TCC? These Aims will be addressed using samples, specifically pre-treatment biopsies and immunotherapy-treated cystectomy specimens, from patients with localized TCC treated with neoadjuvant atezolizumab (anti-PD-L1) before cystectomy as part of an ongoing clinical trial, as well as patients from a companion cohort of non-immunotherapy-treated TCC patients (standard of care). Aim 1 addresses effects of anti-PD-L1 on Treg number and distribution via flow cytometric and immunohistochemical comparison of atezolizumab-treated cystectomies and either paired pre-treatment biopsies or standard of care cystectomies. Aim 2 uses T cell receptor (TCR) sequencing of Tregs from atezolizumab-treated and standard of care cystectomies as well as paired pre-treatment biopsies, to understand how anti-PD-L1 modulates Treg TCR repertoire diversity as well as the frequency of specific Treg clonotypes. This will reveal novel roles for Tregs in responsiveness to anti-PD-L1 in TCC, leading to avenues for therapeutic targeting of Tregs or enhancement of immune responses to specific tumor antigens that are suppressed by Tregs.
Similar projects All >
Sorted by: Start Date
Project list item
Targeting FGF in Bladder cancer after Neoadjuvant Immunotherapy and Surgery

American Association For Cancer Research to Joshua James Meeks

USD 25,000
2019 - 2020
Project list item
Phase 1/2 Study of Modern Immunotherapy in BCG-Relapsing Urothelial Carcinoma of the Bladder - (ADAPT-BLADDER)

National Cancer Institute to NOAH M HAHN

USD 656,816
2019 - 2024
Project list item
Defining the impact of intra-tumoral morphologic, immune and mutational heterogeneity in urothelial carcinoma

National Cancer Institute to HIKMAT AL-AHMADIE

USD 410,835
2019 - 2024
Project list item
Ultrasound-based diagnostic and monitoring of bladder cancer treatment with drug released from nanoparticles

National Cancer Institute to JOE ASSOULINE, YI LUO

USD 350,240
2018 - 2020

System

Categories
  • FOR (ANZSRC)

    1107 Immunology

  • RCDC

    Cancer

  • RCDC

    Clinical Research

  • RCDC

    Urologic Diseases

  • HRCS HC

    Inflammatory and Immune System

  • HRCS RAC

    5.1 Pharmaceuticals

  • Health Research Areas

    Biomedical

  • Broad Research Areas

    Clinical Medicine and Science